OXURION NV

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Oxurion is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
Oxurion is aiming to build global franchise in treatment of retinal vascular disorders based on the successful development of its two novel therapeutics:
- THR-149, a plasma kallikrein inhibitor being developed as potential new standard of care for the 40% of DME patients who respond sub-optimally to anti-VEGF therapy.
- THR-687 is a pan-RGD integrin antagonist developed as potential first line therapy for DME patients. Positive topline results in a Ph1 clinical study assessing THR-687 as treatment for DME were announced in 2020. THR-687 expected to enter a Phase 2 clinical trial in mid-20
Ticker:
OXUR
Exchange:
Euronext
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Belgium
Year Founded:
1991
Main Therapeutic Focus:
Lead Product in Development:
THR-149
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
OXURION NV